Multiple diabetes indicators, one blood sample
SomaSignal® tests turn proteomic data into clinical metrics for diabetes
18 clinical metrics from 55 µL
of blood, including:
- Glucose tolerance
- Resting energy
- Visceral fat
- Cardiorespiratory fitness
- Alcohol impact
- Heart failure
Ideal for clinical trial
monitoring
- Assess comorbidities, including fatty liver and heart disease
- Measure VO2 max without an exercise test
- Determine drug efficacy
- Identify at-risk patients
- Identify patients likely to respond
Stratify patients
Measure drug effects
Anticipate adverse events
Additional resources
White paperDetection of low-abundance serum proteins associated with Prediabetes for predictive and prognostic purposes
Diabetes mellitus refers to a family of metabolic disorders that are characterized by elevated blood glucose concentrations, or hyperglycemia. The International Diabetes Federation estimated that in 2015 there were 415 million diabetes cases worldwide in the 20-79 year old age group and predicted that number to increase to 640 million by 2040. In the whitepaper you will uncover: Predicting disease onset via clinical biomarkers Applying the SomaScan® Assay to accurately identify serum proteins associated with diabetic risk and outcome Other potential applications for the SomaScan Assay in diabetes researchAdditional SomaSignal tests
The CVD, heart failure, and cardiorespiratory fiitness tests make up a subset of 22 SomaSignal tests available for research use. Any or all of the SomaSignal tests are available for a single flat cost.
Contact one of our experts to learn more
The statements herein have not been evaluated by the Food and Drug Administration.